Jazz Pharmaceuticals recruiting for Phase III clinical study
May 31, 2018
Jazz Pharmaceuticals is currently recruiting patients for a Phase III clinical study focused on adults who have narcolepsy with cataplexy (Narcolepsy type 1). The company is evaluating an investigational oxybate product, JZP-258, as a potential treatment for cataplexy and excessive daytime sleepiness (EDS) in adult narcolepsy patients. The 15-006 study is a multi-center study evaluating the efficacy and safety of JZP-258 for the treatment of cataplexy and excessive daytime sleepiness in adult patients with narcolepsy (https://clinicaltrials.gov/ct2/show/NCT03030599).
For more information or to find a site that is enrolling patients near you, please go to https://trials.autocruitment.com/forms/NarcolepsyStudy15-006/ or speak with a Jazz Pharmaceutical clinical trial representative at (650) 496-2951.
There are many other clinical studies addressing sleep disorders currently ongoing; To learn more about current clinical trials in your area, please visit www.clinicaltrials.gov.